M J Rogers

Summary

Affiliation: University of Aberdeen
Country: UK

Publications

  1. doi Biochemical and molecular mechanisms of action of bisphosphonates
    Michael J Rogers
    University of Aberdeen, UK
    Bone 49:34-41. 2011
  2. pmc Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells
    Bhavik Desai
    Department of Biomedical Sciences, Dental School, University of Maryland, Baltimore, MD 21201, USA
    Mol Cancer 6:18. 2007
  3. pmc RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro
    Karen A Sutherland
    Bone and Musculoskeletal Research Programme, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK
    Arthritis Res Ther 11:R58. 2009
  4. ncbi From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates
    M J Rogers
    Bone Research Group, Institute of Medical Sciences, University of Aberdeen, AB25 2ZD, UK
    Calcif Tissue Int 75:451-61. 2004
  5. ncbi New insights into the molecular mechanisms of action of bisphosphonates
    Michael J Rogers
    Bone Research Group, Department of Medicine and Therapeutics, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK
    Curr Pharm Des 9:2643-58. 2003
  6. ncbi Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs
    F P Coxon
    Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK
    Mol Pharmacol 54:631-8. 1998
  7. ncbi Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages
    F P Coxon
    Department of Medicine and Therapeutics, Medical Microbiology, and Pathology, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom
    J Biol Chem 276:48213-22. 2001
  8. ncbi Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages
    A J Roelofs
    Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom
    Curr Pharm Des 16:2950-60. 2010
  9. pmc The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
    Lauren S Whyte
    Institute of Medical Sciences, University of Aberdeen, Aberdeen AB252ZD, United Kingdom
    Proc Natl Acad Sci U S A 106:16511-6. 2009
  10. ncbi Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase
    Keith Thompson
    Bone Research Group, Department of Medicine and Therapeutics, Proctor and Gamble Pharmaceuticals, Health Care Research Center, Mason, Scotland, 45040, United Kingdom
    Biochem Biophys Res Commun 290:869-73. 2002

Collaborators

Detail Information

Publications46

  1. doi Biochemical and molecular mechanisms of action of bisphosphonates
    Michael J Rogers
    University of Aberdeen, UK
    Bone 49:34-41. 2011
    ..These discoveries are also giving insights into some of the adverse effects of bisphosphonates, such as the acute phase reaction that is triggered by inhibition of FPP synthase in peripheral blood monocytes...
  2. pmc Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells
    Bhavik Desai
    Department of Biomedical Sciences, Dental School, University of Maryland, Baltimore, MD 21201, USA
    Mol Cancer 6:18. 2007
    ..Osteopontin is a well-characterized ligand for the alphavbeta3 integrin. The present study was undertaken to elucidate the possible role of osteopontin/alphavbeta3 signaling in prostate cancer cell migration...
  3. pmc RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro
    Karen A Sutherland
    Bone and Musculoskeletal Research Programme, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK
    Arthritis Res Ther 11:R58. 2009
    ....
  4. ncbi From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates
    M J Rogers
    Bone Research Group, Institute of Medical Sciences, University of Aberdeen, AB25 2ZD, UK
    Calcif Tissue Int 75:451-61. 2004
    ..This brief review summarizes our current understanding of these pathways...
  5. ncbi New insights into the molecular mechanisms of action of bisphosphonates
    Michael J Rogers
    Bone Research Group, Department of Medicine and Therapeutics, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK
    Curr Pharm Des 9:2643-58. 2003
    ..Identification of FPP synthase as the target of nitrogen-containing bisphosphonates has also helped explain the molecular basis for the adverse effects of these agents in the GI tract and on the immune system...
  6. ncbi Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs
    F P Coxon
    Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK
    Mol Pharmacol 54:631-8. 1998
    ....
  7. ncbi Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages
    F P Coxon
    Department of Medicine and Therapeutics, Medical Microbiology, and Pathology, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom
    J Biol Chem 276:48213-22. 2001
    ..The anti-resorptive activity of NE10790 is thus likely due to disruption of Rab-dependent intracellular membrane trafficking in osteoclasts...
  8. ncbi Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages
    A J Roelofs
    Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom
    Curr Pharm Des 16:2950-60. 2010
    ..While alternative anti-resorptive therapeutics are becoming available for clinical use, bisphosphonates currently remain the principle drugs used to treat excessive bone resorption...
  9. pmc The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
    Lauren S Whyte
    Institute of Medical Sciences, University of Aberdeen, Aberdeen AB252ZD, United Kingdom
    Proc Natl Acad Sci U S A 106:16511-6. 2009
    ..In addition, this study also brings to light an effect of both the endogenous ligand, LPI, on osteoclasts and of the cannabis constituent, CBD, on osteoclasts and bone turnover in vivo...
  10. ncbi Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase
    Keith Thompson
    Bone Research Group, Department of Medicine and Therapeutics, Proctor and Gamble Pharmaceuticals, Health Care Research Center, Mason, Scotland, 45040, United Kingdom
    Biochem Biophys Res Commun 290:869-73. 2002
    ....
  11. ncbi Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
    H L Benford
    Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK
    Bone 28:465-73. 2001
    ....
  12. ncbi Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis
    Keith Thompson
    Bone Research Group, Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB252ZD, UK
    Mol Pharmacol 69:1624-32. 2006
    ....
  13. pmc Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP
    Anke J Roelofs
    Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
    Br J Haematol 144:245-50. 2009
    ..These observations identify monocytes as the cell type directly affected by bisphosphonates responsible for Vgamma9Vdelta2 T cell activation...
  14. pmc Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro
    L S Whyte
    Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
    Br J Pharmacol 165:2584-97. 2012
    ..Crucially, previous studies have focussed on the effects of cannabinoid ligands in murine bone cells. This study aimed to investigate the effects of cannabinoids on human bone cells in vitro...
  15. ncbi Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
    J E Dunford
    Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, United Kingdom
    J Pharmacol Exp Ther 296:235-42. 2001
    ....
  16. doi Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells
    Fraser P Coxon
    Bone and Musculoskeletal Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
    Bone 42:848-60. 2008
    ..However, BP uptake by non-resorbing cells can be increased when cultured in the presence of resorbing osteoclasts...
  17. doi Activation of γδ T cells by bisphosphonates
    Keith Thompson
    Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Foresterhill, AB25 2ZD, Aberdeen, UK
    Adv Exp Med Biol 658:11-20. 2010
    ..In this chapter we discuss the mechanism of gamma, delta T cell activation by N-BPs and propose that N-BPs may provide a safe and effective means for manipulating gamma,delta T cell activity in future immunotherapeutic approaches...
  18. ncbi A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo
    Alun Hughes
    Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, AB25 2ZD, UK
    Calcif Tissue Int 81:403-13. 2007
    ..No increase in bone formation rate was observed with statin treatment, suggesting that this effect was due to inhibition of osteoclast-mediated resorption rather than increased bone formation...
  19. pmc Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase
    Anke J Roelofs
    Bone Research Group, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK
    J Pharmacol Exp Ther 322:228-35. 2007
    ..Thus, these findings demonstrate a novel strategy for enhancing the antitumor effects of lovastatin...
  20. pmc Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo
    Anke J Roelofs
    Bone and Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, UK
    J Bone Miner Res 25:606-16. 2010
    ..In conclusion, this study shows that in addition to bone-resorbing osteoclasts, bisphosphonates may exert direct effects on bone marrow monocytes in vivo...
  21. doi Functional interaction between sequestosome-1/p62 and autophagy-linked FYVE-containing protein WDFY3 in human osteoclasts
    Lynne J Hocking
    Musculoskeletal Research Programme, Division of Applied Medicine, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK
    Biochem Biophys Res Commun 402:543-8. 2010
    ..The difference in response to starvation between mature osteoclasts and their precursors may begin to explain the cell-specific functional effects of SQSTM1 mutations in PDB...
  22. ncbi Recent advances in understanding the mechanism of action of bisphosphonates
    Fraser P Coxon
    Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
    Curr Opin Pharmacol 6:307-12. 2006
    ..In addition, the identification of BP analogues that inhibit different enzymes in the mevalonate pathway could lead to the development of novel inhibitors of bone resorption with potential applications in the treatment of bone disease...
  23. ncbi Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro
    Keith Thompson
    Bone Research Group, Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom
    J Bone Miner Res 19:278-88. 2004
    ..These studies clarify the probable initial cause of the acute phase response to N-BP drugs and suggest a possible way of preventing this phenomenon...
  24. ncbi Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro
    Julie C Frith
    Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, United Kingdom
    J Bone Miner Res 18:204-12. 2003
    ..The exact molecular basis for the antagonistic effects between bisphosphonates remain to be determined, but could involve competition for cellular uptake by a membrane-bound transport protein...
  25. ncbi Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo
    Fraser P Coxon
    Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
    Bone 37:349-58. 2005
    ....
  26. ncbi Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases
    James E Dunford
    Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Foresterhill, UK
    J Bone Miner Res 21:684-94. 2006
    ..The antiresorptive activity of N-BPs may therefore be caused at least in part, by the accumulation of unprenylated small GTPases, causing inappropriate activation of downstream signaling pathways...
  27. ncbi Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway
    Keith Thompson
    Bone Research Group, Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, AB25 2ZD, United Kingdom
    Blood 107:651-4. 2006
    ....
  28. ncbi The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis
    J C Frith
    Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, UK
    Arthritis Rheum 44:2201-10. 2001
    ..CONCLUSION: These results provide the first direct evidence that the antiinflammatory and antiresorptive effects of clodronate on macrophages and osteoclasts in vivo occur via the intracellular formation of AppCCl2p...
  29. ncbi The role of prenylated small GTP-binding proteins in the regulation of osteoclast function
    F P Coxon
    Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK
    Calcif Tissue Int 72:80-4. 2003
    ..GDIs have not been identified for all small GTPases, but play an important role in the control of the Rho family GTPases...
  30. ncbi Molecular mechanisms of action of bisphosphonates: current status
    Anke J Roelofs
    Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
    Clin Cancer Res 12:6222s-6230s. 2006
    ..These compounds have high affinity for calcium ions and therefore target bone mineral, where they are internalized by bone-resorbing osteoclasts and inhibit osteoclast function...
  31. ncbi Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma
    Sharon Gordon
    Department of Medicine and Therapeutics, University of Aberdeen Medical School, UK
    Br J Haematol 119:475-83. 2002
    ....
  32. ncbi The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5
    Julie C Crockett
    Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom
    Endocrinology 148:5761-8. 2007
    ..Given that CYR61 also stimulates osteoblasts, CYR61 could represent an important bifunctional local regulator of bone remodeling...
  33. ncbi A novel method for efficient generation of transfected human osteoclasts
    A Taylor
    Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
    Calcif Tissue Int 80:132-6. 2007
    ..Moreover, since these osteoclasts maintain the ability to resorb dentine, this technique could prove useful for assessing the role of specific genes/proteins in osteoclast function...
  34. ncbi Isolation and purification of rabbit osteoclasts
    Fraser P Coxon
    Bone Research Group, Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK
    Methods Mol Med 80:89-99. 2003
  35. pmc A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells
    Lesley A Ford
    School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
    Br J Pharmacol 160:762-71. 2010
    ..Here we have assessed the modulation of breast cancer cell migration, orientation and polarization by LPI and GPR55...
  36. ncbi The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity
    Ada Staal
    Osteoporosis Research, Metabolic and Cardiovascular Drug Discovery, Pharmaceutical Research Institute, Bristol Myers Squibb Company, Pennington, New Jersey 08534, USA
    J Bone Miner Res 18:88-96. 2003
    ..However, cerivastatin does not affect bone resorption in the rat TPTX model in vivo...
  37. pmc The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
    Kathryn L Kavanagh
    Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, United Kingdom
    Proc Natl Acad Sci U S A 103:7829-34. 2006
    ..These experiments reveal the molecular binding characteristics of an important pharmacological target and provide a route for further optimization of these important drugs...
  38. doi Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase
    James E Dunford
    Structural Genomics Consortium, The Botnar Research Centre, University of Oxford, Oxford, United Kingdom
    J Med Chem 51:2187-95. 2008
    ..77, p < 0.0001) and the final inhibition of FPPS by N-BPs ( R = 0.74, p < 0.0001) are closely linked to antiresorptive efficacy...
  39. ncbi Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy
    R Graham G Russell
    The Oxford University Institute of Musculoskeletal Sciences, The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom
    Ann N Y Acad Sci 1117:209-57. 2007
    ..As we approach the 40th anniversary of the discovery of their biological effects, there remain further opportunities for using their properties for medical purposes...
  40. ncbi Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite
    Petri P Lehenkari
    Department of Surgery, University of Oulu, Oulu, Finland
    Mol Pharmacol 61:1255-62. 2002
    ..Hence, inhibition of the ADP/ATP translocase by the metabolite AppCCl(2)p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption...
  41. ncbi JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998)
    Steven P Luckman
    J Bone Miner Res 20:1265-74. 2005
  42. ncbi 2.6-Million-year-old stone tools and associated bones from OGS-6 and OGS-7, Gona, Afar, Ethiopia
    Sileshi Semaw
    CRAFT Research Center, 419 N Indiana Avenue, Indiana University, Bloomington, IN 47405, USA
    J Hum Evol 45:169-77. 2003
  43. doi New evidence for hominin carcass processing strategies at 1.5 Ma, Koobi Fora, Kenya
    Briana L Pobiner
    Department of Anthropology, National Museum of Natural History, Smithsonian Institution, MRC 112, 10th and Constitution Avenue, Washington, DC 20560 0112, USA
    J Hum Evol 55:103-30. 2008
    ..These assemblages increase our knowledge of the dietary behavior and ecology of Homo erectus, and provide support for variability in early Pleistocene hominin carcass foraging patterns...
  44. ncbi Cutmarked bones from Pliocene archaeological sites at Gona, Afar, Ethiopia: implications for the function of the world's oldest stone tools
    Manuel Dominguez-Rodrigo
    Departamento de Prehistoria, Universidad Complutense, 28040, Madrid, Spain
    J Hum Evol 48:109-21. 2005
    ..2.5 Ma, although a larger sample of cutmarked bone specimens is necessary to support the latter inference...
  45. ncbi Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
    Cristina Sobacchi
    Institute of Biomedical Technologies, Consiglio Nazionale delle Ricerche, via F Cervi 93, 20090 Segrate, Italy
    Nat Genet 39:960-2. 2007
    ....
  46. pmc Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations
    Matteo M Guerrini
    Istituto di Tecnologie Biomediche, Consiglio Nazionale delle Ricerche, Segrate 20090, Italy
    Am J Hum Genet 83:64-76. 2008
    ..Our results indicate that TNFRSF11A mutations can cause a clinical condition in which severe ARO is associated with an immunoglobulin-production defect...